January 18, 2005 Although the broad market moved higher after Monday’s holiday, the Centient Biotech 200 gave up 4.56 points or .14%, closing at 3359.57, while the NYSE Composite gained .66% and Nasdaq was .87% higher. The biotech stocks that made significant advances today include Aastrom, StemCells and Geron, the stem-cell triumvirate, which did well after a NY Times article, Avanir and Alexion, which announced advances in clinical trials, and Cruxell, whose work with cell-based vaccines gained the company entry into an international task force.
